These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14986280)

  • 1. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
    Sulkowski MS
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S90-7. PubMed ID: 14986280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
    Rivero A; Camacho A; Pérez-Camacho I; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():45-8. PubMed ID: 20116617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.
    Sulkowski MS
    Semin Liver Dis; 2003 May; 23(2):183-94. PubMed ID: 12800071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of atazanavir in simplification regimens].
    Zamora L; Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():14-21. PubMed ID: 20116612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
    East J; Blanton LS
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1081-3. PubMed ID: 22123706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical utility of atazanavir].
    Ribera Pascuet E; Curran A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knee avascular necrosis in HIV patient.
    Declet VR; Salas AS
    Bol Asoc Med P R; 2015; 107(2):24-6. PubMed ID: 26434077
    [No Abstract]   [Full Text] [Related]  

  • 11. [Efficacy of atazanavir in rescue therapy].
    Portilla J; Boix V; Merino E; Reus S
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():22-7. PubMed ID: 20116613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse effects of atazanavir].
    Palacios R; González M; Ruiz J; Santos J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():41-4. PubMed ID: 20116616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of atazanavir in treatment-naive patients].
    Moreno S; Hernández B; Dronda F
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
    Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
    HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir.
    Hamzah L; Campbell L; Wandolo E; Engler B; Cheserem E; Naftalin C; Taylor C; Post FA
    AIDS; 2015 Jan; 29(3):392-4. PubMed ID: 25686688
    [No Abstract]   [Full Text] [Related]  

  • 17. [Atazanavir-induced nephrolithiasis].
    Valencia ME; Moreno V
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
    [No Abstract]   [Full Text] [Related]  

  • 18. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
    Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
    Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
    HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.